公开(公告)号：US20240408071A1

公开(公告)日：2024-12-12

申请号：US18696916

申请日：2022-09-30

Applicant: NATIONAL CENTRE FOR CELL SCIENCE

Inventor： Girdhari LAL ,  Surojit KARMAKAR

IPC: A61K31/4439 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/555 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28

Abstract: The present invention discloses the use of the novel combination comprising HTR2B antagonist and check-point inhibitors/blockers or various classes of chemotherapeutic agents. The present invention also discloses a composition comprising the combination of the present invention. The present combination and composition are found to possess enhanced activity against various cancer, especially tumors, preferably tumors of epithelial origin, selected from the group comprising colon cancer, breast cancer, and melanoma.